시장보고서

상품코드

1584125

에스트로겐 수용체 양성 유방암 치료 시장 : 약제 클래스별, 치료 유형별, 투여 경로별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Estrogen Receptor Positive Breast Cancer Treatment Market, By Drug Class, By Therapy Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 10월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

에스트로겐 수용체 양성 유방암 치료 시장 규모는 2023년에 198억 1,032만 달러에 달하며, 2024-2032년 CAGR 7.90%로 확대

에스트로겐 수용체 양성 유방암 치료 시장 - 시장 역학

유방암 검진·진단에 대한 의식의 향상이 에스트로겐 수용체 양성 유방암 치료 시장의 성장을 촉진

유방암 검진 및 진단에 대한 인식이 높아짐에 따라 에스트로겐 수용체 양성 유방암 치료제 시장의 성장이 크게 촉진될 것입니다. 이는 미국 유방암 재단에 의해 입증되었으며, 조기 발견을 통해 국한된 단계에서 진단된 경우 생존율이 99%까지 증가한다고 보고하고 있습니다. 유방암 인식의 달과 같은 노력과 Susan G. Komen과 같은 단체의 캠페인은 정기적인 검진의 중요성에 대한 일반 대중의 지식을 높여 지난 10년간 유방암 검진율이 30% 증가하는 결과를 가져왔습니다. 또한 미국 암 협회는 유방암의 약 70%가 ER 양성임을 강조하며 이 아형에 특화된 표적 치료의 중요성을 강조하고 있습니다. 의료 서비스 프로바이더가 첨단 선별 기술과 유전자 검사를 일상 진료에 도입함에 따라 효과적인 치료법에 대한 수요가 증가함에 따라 종양학의 중요한 분야인 이 분야 시장 성장을 더욱 촉진할 것으로 예상됩니다.

에스트로겐 수용체 양성 유방암 치료제 시장 - 주요 인사이트

당사의 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032) 동안 연평균 약 7.90%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예상됩니다.

약물 유형별로는 선택적 에스트로겐 수용체 조절제(SERM)가 22023년 가장 높은 시장 점유율을 차지했습니다.

치료 유형별로는 2023년 호르몬 요법이 주요 유형입니다.

투여 경로별로는 2023년 경구제가 주요 유형이 될 것으로 예상됩니다.

지역별로는 북미가 2023년 주요 수입원이었습니다.

에스트로겐 수용체 양성 유방암 치료제 시장 - 세분화 분석 :

에스트로겐 수용체 양성 유방암 치료제 세계 시장은 약물 유형별, 치료 유형별, 투여 경로별, 최종사용자별, 지역별 시장으로 구분됩니다.

선택적 에스트로겐 수용체 조절제, 아로마타제 억제제, 사이클린 의존성 키나아제(CDK) 억제제, PI3K 억제제 등 4가지로 분류됩니다. 선택적 에스트로겐 수용체 조절제(SERM)는 ER 유방암에 대한 효과가 입증되어 가장 높은 순위를 차지했습니다. 그 뒤를 이어 아로마타제 억제제가 폐경 후 여성에게 널리 사용되고 있습니다. 사이클린 의존성 키나아제(CDK) 억제제가 각광을 받고 있는 반면, PI3K 억제제는 다소 낮은 순위를 차지했습니다.

시장은 치료법 유형에 따라 호르몬 요법, 화학요법, 표적 요법, 면역 요법 등 4가지 범주로 나뉩니다. 호르몬 요법은 ER 유방암에 대한 효과로 인해 가장 우선 순위가 높습니다. 표적 치료는 치료의 정확성을 제공하고 그 뒤를 잇습니다. 화학요법은 3위를 차지하며 종종 병용되며, 면역 요법은 신흥 치료법이지만 현재 이 분야에서는 적용도가 낮습니다.

에스트로겐 수용체 양성 유방암 치료제 시장 - 지역적 인사이트

북미는 에스트로겐 수용체 양성 유방암 치료 시장을 선도하고 있으며, 이는 첨단화된 의료 시스템과 높은 인식 수준에 힘입은 바 큽니다. 미국은 National Breast and Cervical Cancer Early Detection Program(미국 유방암 및 자궁경부암 조기발견 프로그램)과 같은 구상을 시행하여 시작 이후 400만 건 이상의 검진을 실시하여 조기발견율을 크게 향상시켰습니다. 하고 있습니다. 유럽도 이에 발맞추어 영국과 같은 국가에서는 유방암 검진 프로그램이 잘 정착되어 약 85%의 여성들이 조기 진단을 받고 있습니다. 아시아태평양, 특히 일본과 인도와 같은 국가에서 유방암 발병률이 증가함에 따라 각국 정부는 인식 개선 캠페인과 검진 구상을 강화하는 데 힘을 쏟고 있습니다. 예를 들어 인도의 National Health Mission은 검진율을 높이기 위해 지역 기반 프로그램을 시작했습니다. 라틴아메리카에서는 유방암에 대한 인식과 치료 옵션에 대한 접근성이 점차 개선되고 있으며, 중동 및 아프리카에서는 유방암 증가에 대응하기 위해 의료 인프라 개선과 환자 교육에 초점을 맞추었습니다.

에스트로겐 수용체 양성 유방암 치료제 시장 - 경쟁 구도:

에스트로겐 수용체 양성 유방암 치료제 시장 경쟁 구도는 북미의 주요 기업이 주도하고 있으며, 아스트라제네카, 화이자와 같은 기업이 혁신적인 치료법으로 선두를 달리고 있습니다.2023년 아스트라제네카는 HER2 양성 유방암을 표적으로 하는 신약 엔허투를 출시하고 종양학 포트폴리오를 더욱 확장했다, 종양학 포트폴리오를 더욱 확장했습니다. 유럽에서는 로슈가 여전히 중요한 경쟁자이며, 다양한 연구기관과 적극적으로 공동연구를 진행하여 맞춤형 의료 접근법을 발전시키고 있습니다. 예를 들어 로슈와 케임브리지 대학과의 공동 연구는 치료 효과를 예측하는 바이오마커를 개발하는 것을 목표로 하고 있습니다. 아시아태평양에서는 노바티스, 다케다제약 등의 기업이 약진하고 있으며, 노바티스는 신흥 시장에서의 암 분야 파이프라인 확장에 투자하고 있습니다. 화이자(Pfizer)의 Array Biopharma 인수와 같은 최근 합병을 통해 유방암 치료제 개발 역량을 강화하고 있습니다. 또한 ER 유방암 병용요법에 초점을 맞춘 제휴가 증가하고 있으며, 이는 혁신과 전략적 제휴를 통해 환자의 미충족 수요를 충족시키기 위해 노력하는 업체들이 치열한 경쟁 구도를 형성하고 있음을 시사하고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 에스트로겐 수용체 양성 유방암 치료 업계

경쟁 대시보드
기업 개요
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company, Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Johnson &Johnson
- Merck &Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Others

제13장 애널리스트의 전방위 전망

KSA 24.11.14

REPORT HIGHLIGHT

Estrogen Receptor Positive Breast Cancer Treatment Market size was valued at USD 19,810.32 Million in 2023, expanding at a CAGR of 7.90% from 2024 to 2032.

The Estrogen Receptor Positive Breast Cancer Treatment Market focuses on therapies targeting estrogen receptor-positive (ER+) breast cancer, which constitutes about 70% of all breast cancer cases and significantly influences treatment decisions. Increasing awareness about breast cancer screening and diagnosis is boosting market growth, as evidenced by the American Cancer Society reporting over 300,000 new cases of breast cancer in the U.S. annually. The rise in targeted therapies and the approval of novel drugs like CDK4/6 inhibitors are transforming treatment paradigms. However, challenges such as high treatment costs and the potential for drug resistance can hinder market expansion. Additionally, the lack of access to advanced therapies in low-income regions represents a restraint. Opportunities lie in the development of combination therapies and personalized medicine approaches, particularly in emerging markets where healthcare systems are evolving to incorporate advanced cancer treatment options, potentially improving patient outcomes and driving market dynamics in the coming years.

Estrogen Receptor Positive Breast Cancer Treatment Market- Market Dynamics

Growing Awareness of Breast Cancer Screening and Diagnosis Drives Growth in the Estrogen Receptor Positive Breast Cancer Treatment Market

Growing awareness of breast cancer screening and diagnosis significantly drives growth in the Estrogen Receptor Positive Breast Cancer Treatment Market, as evidenced by the National Breast Cancer Foundation reporting that early detection can increase survival rates to 99% when diagnosed at localized stages. Initiatives like Breast Cancer Awareness Month and campaigns from organizations such as Susan G. Komen have heightened public knowledge about the importance of regular screenings, leading to a 30% increase in mammogram rates in the past decade. Moreover, the American Cancer Society emphasizes that approximately 70% of breast cancers are ER-positive, highlighting the importance of targeted treatments that cater specifically to this subtype. As healthcare providers increasingly integrate advanced screening techniques and genetic testing into routine care, the demand for effective therapies is expected to rise, further propelling market growth in this vital area of oncology.

Estrogen Receptor Positive Breast Cancer Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.90% over the forecast period (2024-2032)

Based on Drug Class segmentation, Selective Estrogen Receptor Modulators (SERMs) were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Hormonal therapy was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Estrogen Receptor Positive Breast Cancer Treatment Market- Segmentation Analysis:

The Global Estrogen Receptor Positive Breast Cancer Treatment Market is segmented on the basis of Drug Class, Therapy Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Cyclin-Dependent Kinase (CDK) Inhibitors, and PI3K Inhibitors. Selective Estrogen Receptor Modulators (SERMs) rank highest due to their established efficacy in treating ER+ breast cancer. Aromatase inhibitors follow, widely used in postmenopausal women. Cyclin-dependent kinase (CDK) inhibitors are gaining prominence, while PI3K inhibitors rank slightly lower in application.

The market is divided into four categories based on Therapy Type: Hormonal Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy. Hormonal therapy holds the highest priority due to its effectiveness for ER+ breast cancer. Targeted therapy follows closely, offering precision in treatment. Chemotherapy ranks third, often used in combination, while immunotherapy, although emerging, currently has a lower application in this context.

Estrogen Receptor Positive Breast Cancer Treatment Market- Geographical Insights

North America leads the Estrogen Receptor Positive Breast Cancer Treatment Market, driven by advanced healthcare systems and high awareness levels among the population. The U.S. has implemented initiatives like the National Breast and Cervical Cancer Early Detection Program, which provided over 4 million screenings since its inception, significantly improving early detection rates. Europe follows closely, where countries like the UK have established robust breast cancer screening programs, leading to approximately 85% of women being diagnosed at an early stage. In the Asia-Pacific region, rising breast cancer incidence, especially in countries like Japan and India, is prompting governments to enhance awareness campaigns and screening initiatives. For instance, India's National Health Mission has launched community-based programs to increase screening rates. Latin America is experiencing a gradual increase in awareness and access to treatment options, while the Middle East & Africa are focusing on improving healthcare infrastructure and patient education to tackle the rising burden of breast cancer, reflecting a growing commitment to address this significant health issue.

Estrogen Receptor Positive Breast Cancer Treatment Market- Competitive Landscape:

The competitive landscape of the Estrogen Receptor Positive Breast Cancer Treatment Market is characterized by key players in North America, where companies like AstraZeneca and Pfizer lead the charge with innovative therapies. In 2023, AstraZeneca launched its new drug, Enhertu, which targets HER2-positive breast cancer, further expanding its oncology portfolio. In Europe, Roche remains a significant competitor, actively collaborating with various research institutions to advance personalized medicine approaches. For example, Roche's collaboration with the University of Cambridge aims to develop predictive biomarkers for treatment efficacy. In the Asia-Pacific region, companies like Novartis and Takeda are making strides, with Novartis investing in expanding its oncology pipeline in emerging markets. Recent mergers, such as Pfizer's acquisition of Array BioPharma, enhance its capabilities in breast cancer treatment development. Additionally, increasing partnerships focused on combining therapies for ER+ breast cancer signal a robust competitive environment, with companies aiming to address the unmet needs of patients through innovation and strategic collaborations.

Recent Developments:

In October 2024, The FDA approved a new three-drug combination for ER-positive, HER2-negative breast cancer, significantly improving progression-free survival. The treatment includes inavolisib, fulvestrant, and palbociclib, effectively targeting PIK3CA mutations in patients resistant to standard therapies.

In June 2024, AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) have been approved in the EU for advanced ER-positive breast cancer patients with specific biomarker alterations. The combination significantly reduces disease progression risk by 50% compared to Faslodex alone, based on CAPItello-291 trial results.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Others

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Selective Estrogen Receptor Modulators (SERMs)
Aromatase Inhibitors
Cyclin-Dependent Kinase (CDK) Inhibitors
PI3K Inhibitors

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

Hormonal Therapy
Chemotherapy
Targeted Therapy
Immunotherapy

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Intravenous

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Specialty Clinics
Ambulatory Surgical Centers

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Estrogen Receptor Positive Breast Cancer Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Drug Class
- 2.1.2. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Therapy Type
- 2.1.3. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Route of Administration
- 2.1.4. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by End-User
- 2.1.5. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Country
- 2.1.6. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Region
2.2. Competitive Insights

3. Estrogen Receptor Positive Breast Cancer Treatment Key Market Trends

3.1. Estrogen Receptor Positive Breast Cancer Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Estrogen Receptor Positive Breast Cancer Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Estrogen Receptor Positive Breast Cancer Treatment Market Opportunities
3.4. Estrogen Receptor Positive Breast Cancer Treatment Market Future Trends

4. Estrogen Receptor Positive Breast Cancer Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Estrogen Receptor Positive Breast Cancer Treatment Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Estrogen Receptor Positive Breast Cancer Treatment Market Landscape

6.1. Estrogen Receptor Positive Breast Cancer Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Estrogen Receptor Positive Breast Cancer Treatment Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. Selective Estrogen Receptor Modulators (SERMs)
- 7.1.3. Aromatase Inhibitors
- 7.1.4. Cyclin-Dependent Kinase (CDK) Inhibitors
- 7.1.5. PI3K Inhibitors

8. Estrogen Receptor Positive Breast Cancer Treatment Market - By Therapy Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
- 8.1.2. Hormonal Therapy
- 8.1.3. Chemotherapy
- 8.1.4. Targeted Therapy
- 8.1.5. Immunotherapy

9. Estrogen Receptor Positive Breast Cancer Treatment Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Intravenous

10. Estrogen Receptor Positive Breast Cancer Treatment Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Specialty Clinics
- 10.1.4. Ambulatory Surgical Centers

11. Estrogen Receptor Positive Breast Cancer Treatment Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Estrogen Receptor Positive Breast Cancer Treatment Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. AbbVie Inc.
- 12.2.2. Amgen Inc.
- 12.2.3. AstraZeneca PLC
- 12.2.4. Bayer AG
- 12.2.5. Boehringer Ingelheim GmbH
- 12.2.6. Bristol-Myers Squibb Company
- 12.2.7. Daiichi Sankyo Company, Limited
- 12.2.8. Eli Lilly and Company
- 12.2.9. F. Hoffmann-La Roche AG
- 12.2.10. GlaxoSmithKline plc
- 12.2.11. Johnson & Johnson
- 12.2.12. Merck & Co., Inc.
- 12.2.13. Novartis AG
- 12.2.14. Pfizer Inc.
- 12.2.15. Sanofi S.A.
- 12.2.16. Takeda Pharmaceutical Company Limited
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us